Spectrum Pharmaceuticals Inc. (SPPI) announced after the bell Tuesday that Fusilev sales are now expected to be between $10 million and $15 million for the first quarter, and between $80 million and $90 million for the full year 2013.
Spectrum expects full year 2013 revenues of $160 million to $180 million. The consensus estimate is for revenues of $297.33 million.
Spectrum Pharmaceuticals has gapped open dramatically lower Wednesday and is now down 4.43 at $8.00 on the highest volume in 7 months. The stock has tumbled to a new low for the year.
For comments and feedback: editorial@rttnews.com